Seeking Alpha

Bayer hemophilia drug gets label expansion

  • The FDA approves Bayer's (BAYRY) Kogenate FS antihemophilic factor (recombinant) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.
  • In the 84-patient SPINART study, patients under on-demand therapy experienced an average of 15.2x as many bleeds as those on the prophylactic regimen.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: